This indicates that the inhibition of FXR may sensitize the immunotherapy with anit-PD1/PD-L1 antibodies, since PD-L1 expression is a predictive biomarker for immunotherapy in NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.